Tesamorelin
Growth Hormone Releasing Factor Analog
Dosage
10mg / 20mg
Unit Size
1 Vial
// Add to Cart
10mg
$100.00
22 in stock
20mg
$180.00
98 in stock
What is Tesamorelin?
Tesamorelin is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH) — the hypothalamic peptide that signals the pituitary gland to secrete growth hormone. Unlike direct GH administration, Tesamorelin stimulates the body's own pulsatile GH release, preserving natural feedback regulation. It is most studied for its effects on visceral fat reduction and metabolic health.
44 aa
Amino Acid Chain
Pulsatile
GH Release Pattern
GHRH-R
Target Receptor
Key Benefits
Visceral Fat Reduction
Clinically studied for significant reductions in abdominal visceral adipose tissue through GH-mediated lipolysis.
Lean Mass Preservation
Supports preservation and development of lean muscle mass alongside fat reduction.
Metabolic Rate Enhancement
Increases resting energy expenditure through IGF-1 elevation and enhanced substrate oxidation.
IGF-1 Elevation
Drives hepatic IGF-1 production — the downstream mediator responsible for most of GH's anabolic and metabolic effects.
Cardiovascular Markers
Research has shown improvements in lipid profiles and cardiovascular risk factors with Tesamorelin use.
Anti-Aging Support
Restoring youthful GH pulsatility supports cellular regeneration, skin quality, and metabolic health in aging research.
How It Works
Pituitary GHRH Receptor Activation
Tesamorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering the release of growth hormone in natural pulses.
Pulsatile GH Secretion
Rather than a single spike, Tesamorelin produces sustained pulsatile GH release that mirrors the body's natural rhythm, preserving feedback regulation.
IGF-1 Production
Elevated GH signals the liver to produce IGF-1, which mediates the majority of downstream anabolic, lipolytic, and regenerative effects.
Lipolysis & Body Composition
GH and IGF-1 together activate lipase enzymes in adipose tissue, mobilizing stored fat — particularly visceral fat — as a fuel source.
Common Protocol (Research Reference)
1–2 mg
Dose per injection
1×/day
Frequency
8–12 wks
Typical cycle length
Research Use Notice
Tesamorelin is a research peptide not approved by the FDA for human use. This information is for educational purposes only. Always consult a qualified healthcare professional before considering any peptide protocol.